Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-151607-DP for Primary Fascial Closure in Open Ventral Hernia Repair
NCT07226791Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of gemibotulinumtoxinA in ventral hernia, sponsored by AbbVie Inc.. Started Feb 2026; status: recruiting.
02
Drugs
gemibotulinumtoxinA
03
Conditions
ventral hernia
Beyond the preview
Go deeper on NCT07226791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226791.